Anthony W. Butch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anthony W. Butch has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Brian D. Ahrens
UCLA Olympic Analytical Laboratory, Department of Pathology & Laboratory Medicine, David Geffen School of Medicine at UCLA, 2122 Granville Avenue, Los Angeles, CA, 90025-6106, USA
4 shared publicationsNajib Aziz
Department of Epidemiology, Fielding School of Public Health, University of California in Los Angeles, Los Angeles, California, USA
3 shared publicationsRoger Detels
Department of Epidemiology, Fielding School of Public Health, University of California in Los Angeles, Los Angeles, California, USA
3 shared publicationsAlan M. Fukuchi
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA , Los Angeles, California 90095-1713
2 shared publicationsBeth D. Jamieson
Department of Department of Medicine, David Geffen School of Medicine, University of California in Los Angeles, Los Angeles, California, USA
2 shared publicationsBorislav Starcevic
UCLA Olympic Analytical Laboratory, Department of Pathology & Laboratory Medicine Geffen School of Medicine, Reagan UCLA Medical Center Los Angeles CA USA
2 shared publications
Latest Publications
- 29 September 2016
- Published by Wiley in Drug Testing and Analysis
- Vol. 8 (11-12) , 1147-1151
Urinary human chorionic gonadotropin isoform concentrations in doping control samples
Anti‐doping laboratories routinely use immunoassays to measure urinary concentrations of human chorionic gonadotropin (hCG). To minimize immunoassay differences and false positive screen results from inactive isoforms (free β‐subunit (hCGβ), β‐subunit core fragment (hCGβcf)) laboratories now use intact hCG instead of total hCG immunoassays to measure hCG. To determine the distribution of hCG isoforms in urine, we determined the concentrations of intact hCG, hCGβ, and hCGβcf in male urine samples based on immunoassay total hCG concentrations using a sequential immunoextraction and a liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) method. hCG was isolated using antibody‐conjugated magnetic beads and unique tryptic peptides were quantified by LC‐MS/MS. Negative samples with detectable but low total hCG concentrations (1.2–3.5 pmol/L) had intact and hCGβ concentrations <1.2 pmol/L, and hCGβcf concentrations <2.3 pmol/L by LC‐MS/MS. Urine samples from an athlete receiving hCG had intact hCG concentrations ranging from 18.8 to 57.6 pmol/L, hCGβ concentrations <0.7 pmol/L, and hCGβcf concentrations ranging from 94 to 243% of the intact hCG concentration. In 27 atypical samples with total hCG concentrations ranging from 16.7 to 412.7 pmol/L with intact hCG <2.7 pmol/L by immunoassay, all samples had intact hCG concentrations <3.8 pmol/L and hCGβ concentrations <6.2 pmol/L by LC‐MS/MS. hCGβcf concentrations by LC‐MS/MS varied widely and ranged from 1.03 to 21.9 pmol/L. In summary, total hCG immunoassays significantly overestimate hCG concentrations and can produce false positive results. Although the intact hCG immunoassay slightly overestimates hCG concentrations compared to LC‐MS/MS, it can distinguish between cases of hCG use and atypical cases with elevated total hCG concentrations. Copyright © 2016 John Wiley & Sons, Ltd.
- 29 September 2016
- Published by Wiley in Drug Testing and Analysis
- Vol. 8 (11-12) , 1147-1151
Urinary human chorionic gonadotropin isoform concentrations in doping control samples
Anti‐doping laboratories routinely use immunoassays to measure urinary concentrations of human chorionic gonadotropin (hCG). To minimize immunoassay differences and false positive screen results from inactive isoforms (free β‐subunit (hCGβ), β‐subunit core fragment (hCGβcf)) laboratories now use intact hCG instead of total hCG immunoassays to measure hCG. To determine the distribution of hCG isoforms in urine, we determined the concentrations of intact hCG, hCGβ, and hCGβcf in male urine samples based on immunoassay total hCG concentrations using a sequential immunoextraction and a liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) method. hCG was isolated using antibody‐conjugated magnetic beads and unique tryptic peptides were quantified by LC‐MS/MS. Negative samples with detectable but low total hCG concentrations (1.2–3.5 pmol/L) had intact and hCGβ concentrations <1.2 pmol/L, and hCGβcf concentrations <2.3 pmol/L by LC‐MS/MS. Urine samples from an athlete receiving hCG had intact hCG concentrations ranging from 18.8 to 57.6 pmol/L, hCGβ concentrations <0.7 pmol/L, and hCGβcf concentrations ranging from 94 to 243% of the intact hCG concentration. In 27 atypical samples with total hCG concentrations ranging from 16.7 to 412.7 pmol/L with intact hCG <2.7 pmol/L by immunoassay, all samples had intact hCG concentrations <3.8 pmol/L and hCGβ concentrations <6.2 pmol/L by LC‐MS/MS. hCGβcf concentrations by LC‐MS/MS varied widely and ranged from 1.03 to 21.9 pmol/L. In summary, total hCG immunoassays significantly overestimate hCG concentrations and can produce false positive results. Although the intact hCG immunoassay slightly overestimates hCG concentrations compared to LC‐MS/MS, it can distinguish between cases of hCG use and atypical cases with elevated total hCG concentrations. Copyright © 2016 John Wiley & Sons, Ltd.
- 1 February 2016
- Published by Elsevier in Clinical Biochemistry
- Vol. 49 (3) , 282-286
Estimating the hCGβcf in urine during pregnancy
- 1 February 2016
- Published by Elsevier in Clinical Biochemistry
- Vol. 49 (3) , 282-286
Estimating the hCGβcf in urine during pregnancy
- 1 January 2016
- Published by Springer Nature
- Vol. 1383, 247-263
Detection of Stimulants and Narcotics by Liquid Chromatography-Tandem Mass Spectrometry and Gas Chromatography-Mass Spectrometry for Sports Doping Control
Sports drug testing laboratories are required to detect several classes of compounds that are prohibited at all times, which include anabolic agents, peptide hormones, growth factors, beta-2 agonists, hormones and metabolic modulators, and diuretics/masking agents. Other classes of compounds such as stimulants, narcotics, cannabinoids, and glucocorticoids are also prohibited, but only when an athlete is in competition. A single class of compounds can contain a large number of prohibited substances and all of the compounds should be detected by the testing procedure. Since there are almost 70 stimulants on the prohibited list it can be a challenge to develop a single screening method that will optimally detect all the compounds. We describe a combined liquid chromatography-tandem mass spectrometry (LC-MS/MS) and gas chromatography-mass spectrometry (GC-MS) testing method for detection of all the stimulants and narcotics on the World Anti-Doping Agency prohibited list. Urine for LC-MS/MS testing does not require sample pretreatment and is a direct dilute and shoot method. Urine samples for the GC-MS method require a liquid-liquid extraction followed by derivatization with trifluoroacetic anhydride.
- 1 January 2016
- Published by Springer Nature
- Vol. 1383, 247-263
Detection of Stimulants and Narcotics by Liquid Chromatography-Tandem Mass Spectrometry and Gas Chromatography-Mass Spectrometry for Sports Doping Control
Sports drug testing laboratories are required to detect several classes of compounds that are prohibited at all times, which include anabolic agents, peptide hormones, growth factors, beta-2 agonists, hormones and metabolic modulators, and diuretics/masking agents. Other classes of compounds such as stimulants, narcotics, cannabinoids, and glucocorticoids are also prohibited, but only when an athlete is in competition. A single class of compounds can contain a large number of prohibited substances and all of the compounds should be detected by the testing procedure. Since there are almost 70 stimulants on the prohibited list it can be a challenge to develop a single screening method that will optimally detect all the compounds. We describe a combined liquid chromatography-tandem mass spectrometry (LC-MS/MS) and gas chromatography-mass spectrometry (GC-MS) testing method for detection of all the stimulants and narcotics on the World Anti-Doping Agency prohibited list. Urine for LC-MS/MS testing does not require sample pretreatment and is a direct dilute and shoot method. Urine samples for the GC-MS method require a liquid-liquid extraction followed by derivatization with trifluoroacetic anhydride.
- Open Access
- 1 August 2014
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 60 (8) , 1089-1097
Immunoextraction–Tandem Mass Spectrometry Method for Measuring Intact Human Chorionic Gonadotropin, Free β-Subunit, and β-Subunit Core Fragment in Urine
BACKGROUND: Human chorionic gonadotropin (hCG) stimulates testosterone production by the testicles. Because of the potential for abuse, hCG is banned (males only) in most sports and has been placed on the World Anti-Doping Agency list of prohibited substances. Intact hCG, free β-subunit (hCGβ), and β-subunit core fragment (hCGβcf) are the major variants or isoforms in urine. Immunoassays are used by antidoping laboratories to measure urinary hCG. Cross-reactivity with isoforms differs among immunoassays, resulting in widely varying results. We developed a sequential immunoextraction method with LC-MS/MS detection for quantification of intact hCG, hCGβ, and hCGβcf in urine. METHODS: hCG isoforms were immunoextracted with antibody-conjugated magnetic beads and digested with trypsin, and hCGβ and hCGβcf unique peptides were quantified by LC-MS/MS with the corresponding heavy peptides as internal standard. hCG isoform concentrations were determined in urine after administration of hCG, and the intact hCG results were compared to immunoassay results. RESULTS: The method was linear to 20 IU/L. Total imprecision was 6.6%–13.7% (CV), recovery ranged from 91% to 109%, and the limit of quantification was 0.2 IU/L. Intact hCG predominated in the urine after administration of 2 hCG formulations. The window of detection ranged from 6 to 9 days. Mean immunoassay results were 12.4–15.5 IU/L higher than LC-MS/MS results. CONCLUSIONS: The performance characteristics of the method are acceptable for measuring hCG isoforms, and the method can quantify intact hCG and hCGβ separately. The limit of quantification will allow LC-MS/MS hCG reference intervals to be established in nondoping male athletes for improved doping control.
- 1 August 2014
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 60 (8) , 1089-1097
Open AccessImmunoextraction–Tandem Mass Spectrometry Method for Measuring Intact Human Chorionic Gonadotropin, Free β-Subunit, and β-Subunit Core Fragment in Urine
BACKGROUND: Human chorionic gonadotropin (hCG) stimulates testosterone production by the testicles. Because of the potential for abuse, hCG is banned (males only) in most sports and has been placed on the World Anti-Doping Agency list of prohibited substances. Intact hCG, free β-subunit (hCGβ), and β-subunit core fragment (hCGβcf) are the major variants or isoforms in urine. Immunoassays are used by antidoping laboratories to measure urinary hCG. Cross-reactivity with isoforms differs among immunoassays, resulting in widely varying results. We developed a sequential immunoextraction method with LC-MS/MS detection for quantification of intact hCG, hCGβ, and hCGβcf in urine. METHODS: hCG isoforms were immunoextracted with antibody-conjugated magnetic beads and digested with trypsin, and hCGβ and hCGβcf unique peptides were quantified by LC-MS/MS with the corresponding heavy peptides as internal standard. hCG isoform concentrations were determined in urine after administration of hCG, and the intact hCG results were compared to immunoassay results. RESULTS: The method was linear to 20 IU/L. Total imprecision was 6.6%–13.7% (CV), recovery ranged from 91% to 109%, and the limit of quantification was 0.2 IU/L. Intact hCG predominated in the urine after administration of 2 hCG formulations. The window of detection ranged from 6 to 9 days. Mean immunoassay results were 12.4–15.5 IU/L higher than LC-MS/MS results. CONCLUSIONS: The performance characteristics of the method are acceptable for measuring hCG isoforms, and the method can quantify intact hCG and hCGβ separately. The limit of quantification will allow LC-MS/MS hCG reference intervals to be established in nondoping male athletes for improved doping control.
- Open Access
- 1 November 2013
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 20 (11) , 1774-1777
Acute HIV-1 Seroconversion with an Unusual Plasma Biomarker Profile
An unusual case of acute primary HIV-1 infection in a man with a high plasma viral load, a 51-fold increase in C-reactive protein, and antibodies against only gp160 is described. Numerous serum cytokine concentrations were elevated during HIV-1 seroconversion.
- 1 November 2013
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 20 (11) , 1774-1777
Open AccessAcute HIV-1 Seroconversion with an Unusual Plasma Biomarker Profile
An unusual case of acute primary HIV-1 infection in a man with a high plasma viral load, a 51-fold increase in C-reactive protein, and antibodies against only gp160 is described. Numerous serum cytokine concentrations were elevated during HIV-1 seroconversion.
- 1 April 2013
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 20 (4) , 590-595
Value of a Quality Assessment Program in Optimizing Cryopreservation of Peripheral Blood Mononuclear Cells in a Multicenter Study
Cryopreservation of peripheral blood mononuclear cells (PBMC) allows assays of cellular function and phenotype to be performed in batches at a later time on PBMC at a central laboratory to minimize assay variability. The Multicenter AIDS Cohort Study (MACS) is an ongoing prospective study of the natural and treated history of human immunodeficiency virus (HIV) infection that stores cryopreserved PBMC from participants two times a year at four study sites. In order to ensure consistent recovery of viable PBMC after cryopreservation, a quality assessment program was implemented and conducted in the MACS over a 6-year period. Every 4 months, recently cryopreserved PBMC from HIV-1-infected and HIV-1-uninfected participants at each MACS site were thawed and evaluated. The median recoveries of viable PBMC for HIV-1-infected and -uninfected participants were 80% and 83%, respectively. Thawed PBMC from both HIV-1-infected and -uninfected participants mounted a strong proliferative response to phytohemagglutinin, with median stimulation indices of 84 and 120, respectively. Expression of the lymphocyte surface markers CD3, CD4, and CD8 by thawed PBMC was virtually identical to what was observed on cells measured in real time using whole blood from the same participants. Furthermore, despite overall excellent performance of the four participating laboratories, problems were identified that intermittently compromised the quality of cryopreserved PBMC, which could be corrected and monitored for improvement over time. Ongoing quality assessment helps laboratories improve protocols and performance on a real-time basis to ensure optimal cryopreservation of PBMC for future studies.
- 1 April 2013
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 20 (4) , 590-595
Value of a Quality Assessment Program in Optimizing Cryopreservation of Peripheral Blood Mononuclear Cells in a Multicenter Study
Cryopreservation of peripheral blood mononuclear cells (PBMC) allows assays of cellular function and phenotype to be performed in batches at a later time on PBMC at a central laboratory to minimize assay variability. The Multicenter AIDS Cohort Study (MACS) is an ongoing prospective study of the natural and treated history of human immunodeficiency virus (HIV) infection that stores cryopreserved PBMC from participants two times a year at four study sites. In order to ensure consistent recovery of viable PBMC after cryopreservation, a quality assessment program was implemented and conducted in the MACS over a 6-year period. Every 4 months, recently cryopreserved PBMC from HIV-1-infected and HIV-1-uninfected participants at each MACS site were thawed and evaluated. The median recoveries of viable PBMC for HIV-1-infected and -uninfected participants were 80% and 83%, respectively. Thawed PBMC from both HIV-1-infected and -uninfected participants mounted a strong proliferative response to phytohemagglutinin, with median stimulation indices of 84 and 120, respectively. Expression of the lymphocyte surface markers CD3, CD4, and CD8 by thawed PBMC was virtually identical to what was observed on cells measured in real time using whole blood from the same participants. Furthermore, despite overall excellent performance of the four participating laboratories, problems were identified that intermittently compromised the quality of cryopreserved PBMC, which could be corrected and monitored for improvement over time. Ongoing quality assessment helps laboratories improve protocols and performance on a real-time basis to ensure optimal cryopreservation of PBMC for future studies.
- 21 February 2013
- Published by Wiley in Drug Testing and Analysis
- Vol. 5 (5) , 377-379
Detection of the selective androgen receptor modulator S‐4 (Andarine) in a doping control sample
- 21 February 2013
- Published by Wiley in Drug Testing and Analysis
- Vol. 5 (5) , 377-379
Detection of the selective androgen receptor modulator S‐4 (Andarine) in a doping control sample
- 10 January 2013
- Published by Wiley in Drug Testing and Analysis
- Vol. 5 (7) , 534-540
Carbon isotope ratio mass spectrometry for detection of endogenous steroid use: A testing strategy
Isotope ratio mass spectrometry (IRMS) testing is performed to determine if an atypical steroid profile is due to administration of an endogenous steroid. Androsterone (Andro) and etiocholanolone (Etio), and/or the androstanediols (5α- and 5β-androstane-3α,17β-diol) are typically analyzed by IRMS to determine the 13C/12C ratio. The ratios of these target compounds are compared to the 13C/12C ratio of an endogenous reference compound (ERC) such as 5β-pregnane-3α,20α-diol (Pdiol). Concentrations of Andro and Etio are high so 13C/12C ratios can easily be measured in most urine samples. Despite the potentially improved sensitivity of the androstanediols for detecting the use of some testosterone formulations, additional processing steps are often required that increase labour costs and turnaround times. Since this can be problematic when performing large numbers of IRMS measurements, we established thresholds for Andro and Etio that can be used to determine the need for additional androstanediol testing. Using these criteria, 105 out of 2639 urine samples exceeded the Andro and/or Etio thresholds, with 52 of these samples being positive based on Andro and Etio IRMS testing alone. The remaining 53 urine samples had androstanediol IRMS testing performed and 3 samples were positive based on the androstanediol results. A similar strategy was used to establish a threshold for Pdiol to identify athletes with relatively 13C-depleted values so that an alternative ERC can be used to confirm or establish a true endogenous reference value. Adoption of a similar strategy by other laboratories can significantly reduce IRMS sample processing and analysis times, thereby increasing testing capacity. Copyright © 2013 John Wiley & Sons, Ltd.
- 10 January 2013
- Published by Wiley in Drug Testing and Analysis
- Vol. 5 (7) , 534-540
Carbon isotope ratio mass spectrometry for detection of endogenous steroid use: A testing strategy
Isotope ratio mass spectrometry (IRMS) testing is performed to determine if an atypical steroid profile is due to administration of an endogenous steroid. Androsterone (Andro) and etiocholanolone (Etio), and/or the androstanediols (5α- and 5β-androstane-3α,17β-diol) are typically analyzed by IRMS to determine the 13C/12C ratio. The ratios of these target compounds are compared to the 13C/12C ratio of an endogenous reference compound (ERC) such as 5β-pregnane-3α,20α-diol (Pdiol). Concentrations of Andro and Etio are high so 13C/12C ratios can easily be measured in most urine samples. Despite the potentially improved sensitivity of the androstanediols for detecting the use of some testosterone formulations, additional processing steps are often required that increase labour costs and turnaround times. Since this can be problematic when performing large numbers of IRMS measurements, we established thresholds for Andro and Etio that can be used to determine the need for additional androstanediol testing. Using these criteria, 105 out of 2639 urine samples exceeded the Andro and/or Etio thresholds, with 52 of these samples being positive based on Andro and Etio IRMS testing alone. The remaining 53 urine samples had androstanediol IRMS testing performed and 3 samples were positive based on the androstanediol results. A similar strategy was used to establish a threshold for Pdiol to identify athletes with relatively 13C-depleted values so that an alternative ERC can be used to confirm or establish a true endogenous reference value. Adoption of a similar strategy by other laboratories can significantly reduce IRMS sample processing and analysis times, thereby increasing testing capacity. Copyright © 2013 John Wiley & Sons, Ltd.
- 7 June 2012
- Published by Springer Nature
- Vol. 902, 115-128
Detection of Prohibited Substances by Liquid Chromatography Tandem Mass Spectrometry for Sports Doping Control
Drug testing for sports doping control programs is extensive and includes numerous classes of banned compounds including anabolic androgenic steroids, β2-agonists, hormone antagonists and modulators, diuretics, various peptide hormones, and growth factors. During competition, additional compounds may also be prohibited such as stimulants, narcotics, cannabinoids, glucocorticosteroids, and beta-blockers depending both on the sport and level of competition. Each of these classes of compounds can contain many prohibited substances that must be identified during the testing procedure. Various methods that have been designed to detect a large number of compounds in different drug classes are highly desirable as initial screening tools. Liquid chromatography/tandem mass spectrometry (LC-MS/MS) is widely used by anti-doping testing laboratories for this purpose and several rapid methods have been described to simultaneously detect different classes of compounds. Here, we describe a simple urine sample cleanup procedure that can be used to detect numerous anabolic androgenic steroids, β2-agonists, hormone antagonists and modulators, glucocorticosteroids, and beta-blockers by LC-MS/MS.
- 7 June 2012
- Published by Springer Nature
- Vol. 902, 115-128
Detection of Prohibited Substances by Liquid Chromatography Tandem Mass Spectrometry for Sports Doping Control
Drug testing for sports doping control programs is extensive and includes numerous classes of banned compounds including anabolic androgenic steroids, β2-agonists, hormone antagonists and modulators, diuretics, various peptide hormones, and growth factors. During competition, additional compounds may also be prohibited such as stimulants, narcotics, cannabinoids, glucocorticosteroids, and beta-blockers depending both on the sport and level of competition. Each of these classes of compounds can contain many prohibited substances that must be identified during the testing procedure. Various methods that have been designed to detect a large number of compounds in different drug classes are highly desirable as initial screening tools. Liquid chromatography/tandem mass spectrometry (LC-MS/MS) is widely used by anti-doping testing laboratories for this purpose and several rapid methods have been described to simultaneously detect different classes of compounds. Here, we describe a simple urine sample cleanup procedure that can be used to detect numerous anabolic androgenic steroids, β2-agonists, hormone antagonists and modulators, glucocorticosteroids, and beta-blockers by LC-MS/MS.
- 1 July 2011
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 57 (7) , 943-947
The Quest for Clean Competition in Sports: Are the Testers Catching the Dopers?
The practice of using prohibited substances to enhance sports performance (typically referred to as “doping”) is a very old practice that has been with us for centuries. To ensure harmonized, coordinated, and effective antidoping programs, the World Anti-Doping Agency (WADA)6 was created as an independent agency. The WADA publishes a list of prohibited substances annually, and the presence of any prohibited substance or metabolite in an athlete's sample constitutes an antidoping rule violation. Over the years, testing programs have continued to expand, and WADA-accredited laboratory testing has increased 40% over the last 3 years. The issue of sports doping has gained widespread attention, and the public seems to be continually reminded of athletes who dope and the potential growing problem of doping at all levels of competition. Surprisingly, an athlete has come forward and stated that it is impossible to win a cycling event like the Tour de France without doping. In this Q&A article, 4 leaders with different roles in the antidoping effort have been asked to comment on the success of antidoping programs and major challenges facing antidoping programs, elite athletes, and laboratories in the fight to maintain fair and clean competition. According to WADA statistics, only a small percentage of athletes who are tested test positive for prohibited substances. Do you believe that the use of prohibited substances is more widespread? John A. Lombardo: Establishing the prevalence of prohibited-substances use by results of drug testing would be similar to establishing the prevalence of driving under the influence of alcohol by the number of arrests for drinking and driving. A common goal of all drug-testing programs is to level the playing field so that athletes do not feel they have to use performance-enhancing drugs or prohibited substances to be competitive. Drug-testing programs serve the dual purpose of …
- 1 July 2011
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 57 (7) , 943-947
The Quest for Clean Competition in Sports: Are the Testers Catching the Dopers?
The practice of using prohibited substances to enhance sports performance (typically referred to as “doping”) is a very old practice that has been with us for centuries. To ensure harmonized, coordinated, and effective antidoping programs, the World Anti-Doping Agency (WADA)6 was created as an independent agency. The WADA publishes a list of prohibited substances annually, and the presence of any prohibited substance or metabolite in an athlete's sample constitutes an antidoping rule violation. Over the years, testing programs have continued to expand, and WADA-accredited laboratory testing has increased 40% over the last 3 years. The issue of sports doping has gained widespread attention, and the public seems to be continually reminded of athletes who dope and the potential growing problem of doping at all levels of competition. Surprisingly, an athlete has come forward and stated that it is impossible to win a cycling event like the Tour de France without doping. In this Q&A article, 4 leaders with different roles in the antidoping effort have been asked to comment on the success of antidoping programs and major challenges facing antidoping programs, elite athletes, and laboratories in the fight to maintain fair and clean competition. According to WADA statistics, only a small percentage of athletes who are tested test positive for prohibited substances. Do you believe that the use of prohibited substances is more widespread? John A. Lombardo: Establishing the prevalence of prohibited-substances use by results of drug testing would be similar to establishing the prevalence of driving under the influence of alcohol by the number of arrests for drinking and driving. A common goal of all drug-testing programs is to level the playing field so that athletes do not feel they have to use performance-enhancing drugs or prohibited substances to be competitive. Drug-testing programs serve the dual purpose of …